Market Analysis 

The global multiple sclerosis treatment market is likely to grow at a 3.5% CAGR between 2017- 2023, according to the recent Market Research Future (MRFR) report. Multiple sclerosis or MS is a potentially disabling disease both of the spinal cord the brain. The symptoms, duration, and severity can differ from one person to another. Some of the common symptoms include impaired coordination, fatigue, pain, and vision loss.

Multiple Sclerosis Treatment Market Drivers and Restraints 

Various factors are adding to the global multiple sclerosis treatment market share. These factors, as per the new MRFR report, include the need for better treatment, greater screening, and increasing patient population, increasing aging population, high unmet need of drugs to treat the disease, extensive research and development pipelines, and increased research in multiple sclerosis to create innovative therapies. Additional factors adding market growth include rapid product launches, rising mergers acquisitions amid manufacturing companies, increased focus on drug discovery, the launch of new and efficient therapies, and fast delivery of new treatments.

On the contrary, the lack of effective treatment and cure and gap between early diagnosis the actual initiation of therapy are factors that may limit the multiple sclerosis treatment market growth over the forecast period.

Market Segmentation 

The MRFR report provides an inclusive segmental analysis of the global multiple sclerosis treatment market based on drug type, route of administration, diagnosis, and end users.

By drug type, the multiple sclerosis treatment market is segmented into immunosuppressants, immunomodulators, and others.

By route of administration, the multiple sclerosis treatment market is segmented into oral, injectable, and others.

By diagnosis, the multiple sclerosis treatment market is segmented into lumbar puncture, simple electrical stimulation tests, Magnetic Resonance Imaging (MRI) scans, and others.

By end users, the multiple sclerosis treatment market is segmented into clinics, hospitals, and others.

Regional Analysis 

Based on the region, the global multiple sclerosis treatment market covers the recent trends and growth opportunities across Europe, North America, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, North America will lead the market over the forecast period. The US is the key contributor in the region for increased research institutes for improved treatments, rapid development in the medical industry, and increasing hospitalization procedures owing to higher healthcare penetration. Besides, good reimbursement policies, consolidation of large healthcare players, and major hospitals, especially in developed countries are also adding market growth.

The global multiple sclerosis treatment market in Europe is likely to hold the second-largest share over the forecast period for increasing healthcare penetration and the growing healthcare industry. Germany France are the major contributors in the market for the presence of a large pharmaceutical industry in Germany.

 The global multiple sclerosis treatment market in the APAC region is predicted to grow at a fast pace over the forecast period. India China are the major contributors in the region for the large unmet needs and rapidly growing healthcare sector. Besides, the growing penetration of the healthcare sector and the huge patient population having different infectious diseases are also adding market growth.

Key Players 

Notable players profiled in the global multiple sclerosis treatment market report include AbbVie (US), Novartis (Switzerland), Merck (US), Sanofi Aventis (France), Pfizer Inc. (US), Biogen Idec (US), Bayer Healthcare (Germany), and Teva Pharmaceuticals (Isreal).